Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185158 | 0.82 | PDE4A (0.34) | LMNASMN1; SMN2METSLC22A12IDO1 | |
| SCHEMBL23528183 | 0.76 | PDGFRA (0.56) | METPDGFRAPDGFRBKDR | |
| SCHEMBL29206714 | 0.75 | CSNK2A1 (0.35) | — | |
| SCHEMBL13457873 | 0.73 | TLR8 (0.38) | SMN1; SMN2PDGFRAPDGFRBKDR | |
| SCHEMBL30298724 | 0.73 | NCF1 (0.43) | SMN1; SMN2SLC22A12 | |
| SCHEMBL30227708 | 0.70 | MPO (0.54) | METPDGFRAPDGFRBKDR | |
| SCHEMBL23882523 | 0.70 | MPO (0.54) | METPDGFRAPDGFRBKDR | |
| SCHEMBL23146986 | 0.70 | AXL (0.42) | LMNASMN1; SMN2IDO1ALDH1A1AXL | |
| SCHEMBL23882454 | 0.70 | FGFR2 (0.43) | PDGFRAPDGFRBKDR | |
| SCHEMBL15743523 | 0.70 | PLAU (0.41) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | LMNA 2217/4885SMN1; SMN2 1444/4885MET 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.